Hepatitis C virus (HCV), a spherical, enveloped, positive-strand RNA virus.
Transmission of HCV is bloodborne and most often involves exposure to contaminated needles or syringes or receipt of blood or blood products that have not been screened for HCV. Although infrequent, HCV can be transmitted through other procedures that involve blood exposure, such as tattooing, during sexual contact, or perinatally from mother to child.
Globally, an estimated 130–150 million people are living with HCV infection (chronically infected), and more than 700,000 were estimated to have died from HCV-related liver disease in 2013. Although the quality of epidemiologic data varies widely across countries and regions, the most recent global estimates indicate that the prevalence of HCV infection is <1.5% in many developed countries, including the United States (Map 3-5). The prevalence is higher (≥1.5%) in several countries in Latin America, Eastern Europe and the former Soviet Union, and certain countries in Africa, the Middle East, and Asia; the prevalence is reported to be highest (approximately 10%) in Egypt. The most frequent current mode of transmission in the United States and most developed countries is through sharing drug-injection equipment. In countries where HCV is more common (≥1.5% prevalence), the predominant mode of transmission is from unsafe injections and other health care exposures where infection control practices are poor. Travelers’ risk for contracting HCV infection is generally low, but they should exercise caution, as the following activities can result in blood exposure:
- Receiving blood transfusions that have not been screened for HCV
- Having medical or dental procedures
- Activities such as acupuncture, tattooing, being shaved, or injection drug use in which equipment has not been adequately sterilized or disinfected or in which contaminated equipment is reused
- Working in health care fields (medical, dental, or laboratory) that entail direct exposure to human blood
HCV is a major cause of cirrhosis and hepatocellular cancer and is the leading reason for liver transplantation in the United States. Most people (80%) with acute HCV infection have no symptoms. If symptoms occur, they may include loss of appetite, abdominal pain, fatigue, nausea, dark urine, and jaundice. Of those infected, as many as 75% will remain infected unless treated with antiviral medications. For people who develop chronic HCV infection, the most common symptom is fatigue. Cirrhosis develops in approximately 10%–20% of people after 20 years of chronic infection. This progression is often clinically silent, and evidence of liver disease may not occur until late in the course of the disease. HCV testing is required for diagnosis. However, testing is not routinely provided in many countries, and most HCV-infected people are unaware of their infection.
Two major types of tests are available: IgG assays for HCV antibodies and nucleic acid amplification testing to detect HCV RNA in blood (viremia). Assays for IgM, to detect early or acute infection, are not available. Approximately 70%–75% of people who seroconvert to anti-HCV, indicative of acute infection, will progress to chronic infection and persistent viremia. Because a positive HCV antibody test cannot discriminate between someone who was previously infected but resolved or cleared the infection and someone with current infection, it is essential that HCV RNA testing follow a positive HCV antibody test to identify people with current (chronic) HCV infection. Hepatitis C is a nationally notifiable disease.
Treatment for hepatitis C continues to evolve rapidly. Since 2014, several new all-oral direct-acting antiviral agents have been approved for use both in the United States and other countries. These new treatment regimens are of short duration (typically 12 weeks) with few side effects and cure rates exceeding 90% for those who complete treatment. However, the effectiveness of these antiviral therapies differs to some extent by genotype. Travelers who think they may have been exposed should see their health care provider upon return and get tested for HCV, and if found to have evidence of infection, be referred for care and evaluated for treatment, including genotyping as appropriate. Other drugs and therapeutic combinations in development show promise of further improvements in therapy for HCV infection. The most up-to-date treatment guidelines and information can be found at www.hcvguidelines.org.
No vaccine is available to prevent HCV infection, nor does immune globulin provide protection. Before traveling, people should check with their health care providers to understand the potential risk of infection and any precautions they should take. When seeking medical or dental care, travelers should be alert to the use of medical, surgical, or dental equipment that has not been adequately sterilized or disinfected; reuse of contaminated equipment; and unsafe injection practices (such as reuse of disposable needles and syringes). HCV and other bloodborne pathogens can be transmitted if instruments are not sterile or the clinician does not follow other proper infection-control procedures (washing hands, using latex gloves, and cleaning and disinfecting surfaces and instruments). In some parts of the world, such as parts of sub-Saharan Africa, blood donors may not be screened for HCV. Travelers should be advised to consider the health risks if they are thinking about getting a tattoo or body piercing or having a medical procedure in areas where adequate sterilization or disinfection procedures might not be practiced. Travelers should be advised to seek testing for HCV upon return if they received blood transfusions or sustained other blood exposures for which they could not assess the risks.
CDC website: www.cdc.gov/hepatitis/HCV
- American Association for Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA). Recommendations for testing, managing, and treating hepatitis C. [updated 2014 Aug 11; cited 2016 Sep. 23]. Available from: http://www.hcvguidelines.org/.
- Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012 Jul;55 Suppl 1: S10–5. [PMID:22715208]
- CDC. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):362–5. [PMID:23657112]
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10; 385(9963):117–71. [PMID:25530442]
- Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014 Nov; 61(1 Suppl):S45–57. [PMID:25086286]
- Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015 Jan;61(1):77–87. [PMID:25069599]
- Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014 Jan;59(1):318–27. [PMID:24115039]
- Ward JW, Mermin JH. Simple, effective, but out of reach? Public health implications of HCV drugs. N Engl J Med. 2015 Dec 31;373(27):2678–80. [PMID:26575359]
- Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014 Nov;61(1 Suppl):S58–68. [PMID:25443346]
- World Health Organization. Hepatitis C. 2015 [updated July 2015; cited 2016 Sep. 23]. Available from: http://www.who.int/mediacentre/factsheets/fs164_apr2014/en/.